American Association for Cancer Research
23266066cir180711-sup-209985_2_supp_5498831_pqy074.pdf (53.65 kB)

Figure S3 from IRF1 Inhibits Antitumor Immunity through the Upregulation of PD-L1 in the Tumor Cell

Download (53.65 kB)
journal contribution
posted on 2023-04-04, 00:42 authored by Lulu Shao, Weizhou Hou, Nicole E. Scharping, Frank P. Vendetti, Rashmi Srivastava, Chandra Nath Roy, Ashley V. Menk, Yiyang Wang, Joe-Marc Chauvin, Pooja Karukonda, Stephen H. Thorne, Veit Hornung, Hassane M. Zarour, Christopher J. Bakkenist, Greg M. Delgoffe, Saumendra N. Sarkar

Supplementary Figure S3






Multiple studies have associated the transcription factor IRF1 with tumor-suppressive activities. Here, we report an opposite tumor cell–intrinsic function of IRF1 in promoting tumor growth. IRF1-deficient tumor cells showed reduced tumor growth in MC38 and CT26 colon carcinoma and B16 melanoma mouse models. This reduction in tumor growth was dependent on host CD8+ T cells. Detailed profiling of tumor-infiltrating leukocytes did not show changes in the various T-cell and myeloid cell populations. However, CD8+ T cells that had infiltrated IRF1-deficieint tumors in vivo exhibited enhanced cytotoxicity. IRF1-deficient tumor cells lost the ability to upregulate PD-L1 expression in vitro and in vivo and were more susceptible to T-cell–mediated killing. Induced expression of PD-L1 in IRF1-deficient tumor cells restored tumor growth. These results indicate differential activity of IRF1 in tumor escape.